Sapanisertib/Serabelisib

N/A

Report date: 2026/03/11 20:02:12

Base Information

Drug NameSapanisertib/Serabelisib
Drug Alias NamePIKTORFTH-001/FTH-003
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionmTOR Complex 2 inhibitorsMammalian target of Rapamycin (mTORC1) inhibitorsPhosphatidylinositol 3 kinase alpha inhibitors
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2Phosphatidylinositol 3 kinase alpha
Therapy Area/IndicationsEndometrial Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes SapanisertibSerabelisib
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesFaeth Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesFaeth Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsEndometrial Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A